Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9 Genitourinary 5 Thoracic 3 CNS 3 Breast 3 Sarcoma 1 Plasma cell 1 NET 1 Myeloid 1 Gynecologic 1 Endocrine 1 Dermatologic 1

Conditions

Neuroendocrine Tumors 69 Pheochromocytoma 8 Gastro-enteropancreatic neuroendocrine tumor 8 Carcinoma, Neuroendocrine 8 Paraganglioma 7 Carcinoid Tumor 7 Adenoma, Islet Cell 7 Sarcoma 6 Thyroid Neoplasms 5 Pancreatic Neoplasms 5 Neoplasms 5 Melanoma 5 Breast Neoplasms 5 Prostatic Neoplasms 4 Ovarian Neoplasms 4 Neuroblastoma 4 Neoplasm Metastasis 4 Mesothelioma 4 Carcinoma, Merkel Cell 4 Carcinoma 4 Stomach Neoplasms 3 Neuroectodermal Tumors, Primitive 3 Meningioma 3 Liver Neoplasms 3 Gallbladder Neoplasms 3 Colorectal Neoplasms 3 Colonic Neoplasms 3 Cholangiocarcinoma 3 Central Nervous System Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3

Interventions

lutetium Lu 177 dotatate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × NET × 90 days × Clear all

NCT04954820 2026-06-04

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting

Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡